{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:20:10Z","timestamp":1765423210444,"version":"3.37.3"},"reference-count":26,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2021,3,21]]},"DOI":"10.1080\/10428194.2020.1850719","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T01:51:06Z","timestamp":1606441866000},"page":"791-800","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"62","author":[{"given":"Jeff P.","family":"Sharman","sequence":"first","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habte A.","family":"Yimer","sequence":"additional","affiliation":[{"name":"Texas Oncology, US Oncology Research, Tyler, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Boxer","sequence":"additional","affiliation":[{"name":"Arizona Oncology, US Oncology Research, Tucson, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Babu","sequence":"additional","affiliation":[{"name":"Fort Wayne Medical Oncology, Fort Wayne, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[{"name":"Genentech Inc, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, OR, USA"},{"name":"City of Hope National Medical Center, Duarte, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the GIBB study investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31738"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192328"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"volume-title":"GAZYVA (obinutuzumab) injection prescribing information","year":"2020","key":"e_1_3_6_10_1","unstructured":"GAZYVA (obinutuzumab) injection prescribing information. South San Francisco (CA): Genentech, Inc. A Member of the Roche Group; 2020."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0146-5"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-870238"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.014"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1305"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792333"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-304683"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0132-y"},{"volume-title":"IMBRUVICA (ibrutinib) prescribing information","year":"2020","key":"e_1_3_6_25_1","unstructured":"IMBRUVICA (ibrutinib) prescribing information. Sunnyvale (CA): Pharmacyclics LLC; 2020."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000275"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2020.1850719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:22:58Z","timestamp":1732296178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2020.1850719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3,21]]}},"alternative-id":["10.1080\/10428194.2020.1850719"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2020.1850719","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}